This study is an open label, prospective study to evaluate the safety of Stapokibart Injection in subjects with SAR.
Participants aged 18 years or older at the time of informed consent and provide voluntary informed consent to participate in the study before inclusion in the study.
Physician decision to treat the participant with Stapokibart Injection for SAR (according to the China-specific prescribing information) made prior to and independently of the participant's participation in the study.
Known history of allergic reaction to Stapokibart Injection.
Participants currently or plan participating in any interventional clinical trial.
Participants with hematologic malignancies.
Women with pregnant.